Medicine
Selarsdi 45 mg/0.5 mL injection
Selarsdi 45 mg/0.5 mL injection is a prescription medicine containing Ustekinumab for subcutaneous use, marketed by Teva Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store SELARSDI vials and prefilled syringes refrigerated between 36°F to 46°F…
Key facts
- Active ingredient (INN)
- Ustekinumab
- Brand
- Selarsdi
- Strength
- 45 mg/0.5 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 vial of 0.5 mL, 1 tray of 0.5 mL
- Marketing authorisation holder
- Teva Pharmaceuticals
- Manufacturer
- Teva Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store SELARSDI vials and prefilled syringes refrigerated between 36°F to 46°F (2°C to 8°C). Do not freeze. If needed, individual prefilled syringes may be stored at room temperature up to 86°F (30°C) for a maximum single period of up to 30 days in the original carton to protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AC05 Ustekinumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 12 March 2025
- Identifiers
- RxCUI 2705382, 2705389, 2705393 +5DailyMed set ID 87f75b59-e48b-47c7-a4c0-5fe5965660e7NDC 51759-505Application BLA761343
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / .5 mL in 1 vial | 51759-505-13 | Teva Pharmaceuticals | 16 October 2025 |
| 1 tray in 1 carton / 1 syringe, glass in 1 tray / .5 mL in 1 syringe, glass | 51759-505-32 | Teva Pharmaceuticals | 12 March 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Ustekinumab 45 mg/0.5 mL injection.
- Ustekinumab 45 mg/0.5 mL injectionAvailable on request—US FDA7 packs Cold chain
- Pyzchiva 45 mg/0.5 mL injectionAvailable on requestCordavisUS FDA4 packs Cold chain
- Wezlana 45 mg/0.5 mL injectionAvailable on requestNuvailaUS FDA4 packs Cold chain
- Otulfi 45 mg/0.5 mL injectionAvailable on requestFresenius KabiUS FDA2 packs Cold chain
- Starjemza 45 mg/0.5 mL injectionAvailable on requestHikma PharmaceuticalsUS FDA2 packs Cold chain
- Stelara 45 mg/0.5 mL injectionAvailable on requestJanssen BiotechUS FDA2 packs Cold chain
Other strengths and forms of Ustekinumab
Clinical summary
Ustekinumab is an interleukin-12 antagonist indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy. MedsAcross supplies Ustekinumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about UstekinumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ustekinumab prescribing information (Janssen Biotech) · U.S. National Library of Medicine, DailyMed
- Stelara: European public assessment report (EPAR) · European Medicines Agency
- Fymskina: European public assessment report (EPAR) · European Medicines Agency
Need Selarsdi 45 mg/0.5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.